Veloxis Pharmaceuticals A/S. (11/25/19). "Press Release: Asahi Kasei Group Announces a Recommended Conditional Voluntary Public Offer for Veloxis [Not for any jurisdiction where violation of law]". Copenhagen.

	Organisation	Veloxis Pharmaceuticals A/S (Nasdaq OMX Copenhagen: VELO)
	Today	LifeCycle Pharma A/S
	Organisation 2	Asahi Kasei Pharma Denmark A/S
	Group	Asahi Kasei (Group)
	Product	MeltDose® drug delivery technology
	Product 2	Envarsus XR
	Index term	Veloxis Pharmaceuticals–Asahi Kasei: investment, 201911– recommended cash offer DKK 8.9b ($1.3b) by Asahi Kasei Pharma Denmark A/S
	Person	Collard, Craig (Veloxis Pharmaceuticals 201911 CEO)
	Person 2	Heffernan, James (Nova Capital 201409 CEO of Bibby Scientific Ltd)

Original document
accessed by [iito] on 2019-11-26

Record changed: 2023-06-05

Picture Berlin Partner Voices Tim Huse BIH Digital Health 650x200px

More documents for Veloxis Pharmaceuticals A/S (Nasdaq OMX Copenhagen: VELO)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]